- Home
- / CMG Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
CMG Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
₩105.2 B
FY, 2025
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 58.6B | 64.5B | 69.5B | 82.2B | 93.9B | 99.1B | 105.2B |
| Cost of goods sold | 24.7B | 24.7B | 31.7B | 36.3B | 49.3B | 52.5B | 43.4B |
| Gross profit | 34.7B | 41.4B | 38.0B | 46.3B | 44.8B | 46.7B | 61.8B |
| Gross profit margin, % | 59.1% | 64.2% | 54.7% | 56.3% | 47.7% | 47.1% | 58.8% |
| Operating expense total | 29.2B | 35.5B | 33.7B | 40.6B | 39.1B | 42.3B | 62.4B |
| Depreciation and amortization | 2.2B | 3.7B | 3.0B | 2.6B | 2.6B | 4.5B | 8.2B |
| EBITDA | 5.4B | 5.8B | 2.8B | 1.9B | 6.8B | 3.3B | (2.0B) |
| EBITDA margin, % | 9.2% | 9.0% | 4.0% | 2.3% | 7.3% | 3.3% | -1.9% |
| EBIT | 2.5B | 1.7B | (510.9M) | (1.1B) | 3.9B | (2.4B) | (10.7B) |
| EBIT margin, % | 4.2% | 2.7% | -0.7% | -1.3% | 4.2% | -2.4% | -10.2% |
| Interest income | 1.1B | 840.8M | 1.8B | 2.0B | 3.8B | 3.1B | 2.9B |
| Interest expense | 8.6M | 22.9M | 20.7M | 15.3M | 79.5M | 2.5B | 3.2B |
| Pre tax profit | 3.8B | 568.8M | 3.5B | (1.3B) | 6.7B | 2.9B | (11.8B) |
| Income tax expense | 785.4M | 353.8M | 383.6M | (867.0M) | 275.7M | 185.6M | (1.8B) |
| Net Income | 3.1B | 215.0M | 3.2B | (388.1M) | 6.5B | 2.7B | (10.1B) |